ArticleJournal of autism and developmental disorders2026
Vaccine Hesitancy in Autism Spectrum Disorder: A Systematic Review With Meta-Analyses.
Article in Journal of autism and developmental disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protecting vaccine confidence: a core function of national immunization programs.Public health reviews · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis systematic review and meta-analysis examined vaccine hesitancy and related vaccination behaviours in autism spectrum disorder (ASD)-related populations. We aimed to quantify the burden of hesitancy and synthesize evidence on refusal, delay, and under-vaccination among caregivers of children with ASD and, where available, autistic adults.
methodsFollowing PRISMA 2020 and a prospectively registered PROSPERO protocol (CRD420251154536), we searched MEDLINE/PubMed, Web of Science, EBSCO, and TR Dizin from inception to 28 September 2025. Quantitative, qualitative, and mixed-methods studies addressing vaccine hesitancy or vaccination behaviours in ASD-related populations were eligible. Narrative synthesis was undertaken across all included studies, and meta-analysis was performed where outcomes were sufficiently comparable.
resultsTwenty studies were included (16 quantitative, 3 qualitative, 1 mixed-methods). Among studies using a common instrument and threshold (PACV ≥ 50), the pooled prevalence of vaccine hesitancy among caregivers of children with ASD was 23.65% (95% CI 15.87-33.71). Compared with caregivers of neurotypical children, caregivers of children with ASD had higher odds of vaccine hesitancy or refusal (pooled OR = 2.31, 95% CI 1.66-3.22). They also had higher odds than families of children with other neurodevelopmental conditions (pooled OR = 2.23, 95% CI 1.48-3.35). Sibling-focused analyses suggested greater under-vaccination among younger siblings in ASD-affected families (pooled RR = 3.20, 95% CI 2.59-3.96). Narrative findings consistently implicated the disproven MMR-autism claim, safety concerns, and distrust.
conclusionVaccine hesitancy and related under-vaccination appear to be disproportionately concentrated in ASD-affected families. Autism-informed counselling, explicit myth-correction by trusted clinicians, and service adaptations may improve timely vaccine uptake.
Indexed as
Identifiers
42525202What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.